Orphazyme Buy Hold or Sell Recommendation

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>OR</div>
ORPHA -- Denmark Stock  

DKK 104.60  0.80  0.76%

Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding Orphazyme AS is 'Strong Sell'. Macroaxis provides Orphazyme buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ORPHA positions. The advice algorithm takes into account all of Orphazyme AS available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from ORPHA buy-and-hold perspective. Please check Orphazyme Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool.

Search Advice


Time Horizon

Risk Tolerance

Execute Advice
Sell OrphazymeBuy Orphazyme
Strong Sell


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Not Available
For the selected time horizon Orphazyme AS has a mean deviation of 3.94, standard deviation of 5.68 and variance of 32.32
Macroaxis provides advice on Orphazyme AS to complement and cross-verify current analyst consensus">analyst consensus on Orphazyme AS. Our recommendation engine determines the corporation potential to grow exclusively from the perspective of investors current risk tolerance and investing horizon. To make sure Orphazyme is not overpriced, please check all Orphazyme AS fundamentals, including its Debt to Equity as well as the relationship between Cash Flow from Operations and Beta .

Orphazyme Trading Alerts and Improvement Suggestions

Orphazyme AS has very high historical volatility over the last 30 days
Net Loss for the year was (337.5 M).
The company has accumulated about 123.59 M in cash with (326.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.57.

Orphazyme current analysts recommendations

Target Median Price122.50
Target Mean Price121.75
Target High Price135.00
Number Of Analyst Opinions4
Target Low Price107.00
The consensus estimates and target price estimation is comprised of individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Orphazyme Returns Distribution Density

Mean Return-0.08Value At Risk-8.57
Potential Upside8.76Standard Deviation5.68
 Return Density 

Orphazyme Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Orphazyme or Orphazyme AS sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Orphazyme stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Orphazyme stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Alpha over DOW
Beta against DOW=0.0267
Overall volatility
Information ratio =-0.03

Orphazyme Volatility Alert

Orphazyme AS exhibits very low volatility with skewness of -1.07 and kurtosis of 2.89. However, we advise investors to further study Orphazyme AS technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare Orphazyme to competition

Orphazyme Fundamental Vs Peers

FundamentalsOrphazymePeer Average
Return On Equity(152.98) (0.31) 
Return On Asset(67.50) (0.14) 
Current Valuation2.63 B16.62 B
Shares Outstanding27.04 M571.82 M
Price to Book36.75 9.51 
EBITDA(334.21 M)3.9 B
Net Income(337.5 M)570.98 M
Cash and Equivalents123.59 M2.7 B
Cash per Share4.57 5.01 
Total Debt77.11 M5.32 B
Debt to Equity1.46 48.70 
Current Ratio2.25 2.16 
Book Value Per Share2.65 1.93 K
Cash Flow from Operations(326.82 M)971.22 M
Earnings Per Share(16.87) 3.12 
Number of Employees8618.84 K
Market Capitalization2.63 B19.03 B
Z Score20.48.72

About Orphazyme Buy or Sell Advice

When is the right time to buy or sell Orphazyme AS? Buying stocks such as Orphazyme isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily bases. Although Orphazyme investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply. Please read more on our stock advisor page.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was founded in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme is traded on Copenhagen Stock Exchange in Denmark.

Did You Try This Idea?

Run Military Industrial Thematic Idea Now

Military Industrial
Military Industrial Theme
A collection of large United States defense contractors including companies involved in production or distribution of aircraft, ships, vehicles, weaponry, and electronic systems in cooperation with the government. Military Industrial theme has 46 constituents.
View All  Next Launch Military Industrial
Please check Orphazyme Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page